Taisho Pharmaceutical Holdings Insiders
TAIPYDelisted Stock | USD 14.00 0.00 0.00% |
Taisho Pharmaceutical employs about 9.1 K people. The company is managed by 9 executives with a total tenure of roughly 34 years, averaging almost 3.0 years of service per executive, having 1014.89 employees per reported executive. Break down of Taisho Pharmaceutical's management performance can provide insight into the company performance.
Akira Uehara Chairman President Chairman of Subsidiary, Representative Director |
Shigeru Uehara President Vice President and Presidentident of Subsidiary, Director |
Taisho |
Taisho Pharmaceutical Management Team Effectiveness
The company has return on total asset (ROA) of 0.0183 % which means that it generated a profit of $0.0183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0345 %, meaning that it generated $0.0345 on every $100 dollars invested by stockholders. Taisho Pharmaceutical's management efficiency ratios could be used to measure how well Taisho Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Taisho Pharmaceutical Workforce Comparison
Taisho Pharmaceutical Holdings is currently regarded as top stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 169,656. Taisho Pharmaceutical holds roughly 9,134 in number of employees claiming about 5% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 0.08 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09. Taisho Pharmaceutical Notable Stakeholders
A Taisho Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Taisho Pharmaceutical often face trade-offs trying to please all of them. Taisho Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Taisho Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Akira Uehara | President Chairman of Subsidiary, Representative Director | Profile | |
Shigeru Uehara | Vice President and Presidentident of Subsidiary, Director | Profile | |
Tetsu Watanabe | Executive Director | Profile | |
Ken Uehara | MD Director | Profile | |
Shinichi Tanaka | Gen Communications | Profile | |
Jinsei Maruyama | Co Officer | Profile | |
Jun Kuroda | Ex Director | Profile | |
Hideki Iuchi | G Mang | Profile | |
Hisashi Umeoka | Director | Profile |
About Taisho Pharmaceutical Management Performance
The success or failure of an entity such as Taisho Pharmaceutical often depends on how effective the management is. Taisho Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Taisho management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Taisho management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter drugs and prescription pharmaceutical products in Japan and internationally. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan. Taisho Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 9134 people.
Please note, the imprecision that can be found in Taisho Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Taisho Pharmaceutical Holdings. Check Taisho Pharmaceutical's Beneish M Score to see the likelihood of Taisho Pharmaceutical's management manipulating its earnings.
Taisho Pharmaceutical Workforce Analysis
Traditionally, organizations such as Taisho Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Taisho Pharmaceutical within its industry.Taisho Pharmaceutical Manpower Efficiency
Return on Taisho Pharmaceutical Manpower
Revenue Per Employee | 29.4M | |
Revenue Per Executive | 29.8B | |
Net Income Per Employee | 1.4M | |
Net Income Per Executive | 1.5B |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Taisho Pink Sheet
If you are still planning to invest in Taisho Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taisho Pharmaceutical's history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |